Market revenue in 2020 | USD 453.7 million |
Market revenue in 2028 | USD 955.5 million |
Growth rate | 9.8% (CAGR from 2020 to 2028) |
Largest segment | Laboratory technologies |
Fastest growing segment | Online Technologies |
Historical data | 2020 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Laboratory Technologies, Online Technologies |
Key market players worldwide | Thermo Fisher Scientific Inc, Pfizer Inc, Sartorius AG, Stemcell Holdings Inc Ordinary Shares, Illumina Inc, Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Merck KGaA, Qiagen NV, Shimadzu Corp, Eurofins Scientific SE, Charles River Laboratories International Inc, Takara Bio Inc, Olympus Corp, Avantor Inc, Aurora Innovation Inc Class A, Standard BioTools Inc, Celerion, Cole-Parmer, Hartford Schroders International Stk I, Revvity Inc, Fluidigm Corporation, Polyplus-transfection, Hamilton Lane Inc Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to covid-19 vaccine development tools market will help companies and investors design strategic landscapes.
Laboratory technologies was the largest segment with a revenue share of 95.66% in 2020. Horizon Databook has segmented the Japan covid-19 vaccine development tools market based on laboratory technologies, online technologies covering the revenue growth of each sub-segment from 2020 to 2028.
Japan is one of the fastest-growing markets in Asia Pacific region. Japan is the first country to develop a plant-based COVID-19 vaccine. Mitsubishi Tanabe Pharma, a Japanese pharmaceutical company, developed vaccines from a plant at minimal cost with ease in transport.
As of February 2022, the vaccine is under research and development by Medicago, Inc., a Canadian subsidy of Mitsubishi Tanabe Pharma Corp. to assess the practical use. The company used Virus-Like Particles (VLP) extracted from the corps as a proxy of antigens.
The VLPs are built through genetic engineering of organisms, such as Nicotiana Benthamian plants. Last year, the final phase of clinical trials was completed in six countries, and the vaccine showcased 71% efficacy.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan covid-19 vaccine development tools market , including forecasts for subscribers. This country databook contains high-level insights into Japan covid-19 vaccine development tools market from 2020 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account